ENTRY OF STAVUDINE INTO CEREBROSPINAL FLUID OF HIV INFECTED SUBJECTS

司他夫定是一种有效的HIV-1逆转录酶抑制剂，在美国获得许可 1994年。脑脊液司他夫定没有系统评价 已经报告了单次剂量或以下剂量的浓度 稳态条件。提高对司他夫定透皮吸收的认识 进入脑脊液是很重要的，因为需要足够的抑制 中枢神经系统中抑制艾滋病毒复制的浓度 希望能预防或减缓艾滋病痴呆症的发展 很复杂。 该方案将检查司他夫定(D4T)在体内的浓度 HIV感染者择期手术脑脊液检测结果分析 腰椎穿刺术(LP)。研究对象分为两组：1) 那些出于临床考虑而开出司他夫定的人，谁会提供 深入了解在稳定状态下实现的脑脊液浓度； 2)临床未接受司他夫定，但同意接受 在预定的LP之前进行单剂注射，世卫组织将提供关于 敏锐的动力。 这项研究还将确定是否存在一种关系 患者CD4细胞浓度与脑脊液司他夫定疗效之间的关系 条目以及脑脊液白细胞之间是否存在关系 浓度或总蛋白与脑脊液司他夫定的疗效 进入。

Stavudine is a potent HIV-1 reverse transcriptase inhibitor licensed in 1994. No systematic evaluation of cerebrospinal fluid stavudine concentrations has been reported, either for single doses or under steady-state conditions. Improved understanding of stavudine penetration into CSF is important because of the desire for adequate inhibitory concentrations in the central nervous system to suppress HIV replication and hopefully to prevent or slow the development of the AIDS dementia complex. This protocol will examine the concentrations of stavudine (d4T) in cerebrospinal fluid (CSF) of HIV-infected subjects undergoing elective lumbar punctures (LP). Two groups of subjects will be studied: 1) those prescribed stavudine for clinical considerations, who will provide insight into CSF concentrations achieved under steady-state conditions; 2) those not receiving stavudine clinically, but agreeing to take a single dose prior to a scheduled LP, who will provide information on acute dynamics. This study will also determine whether or not a relationship exists between patient CD4 cell concentration and efficiency of CSF stavudine entry and whether or not a relationship exists between CSF white cell concentration or total protein and the efficiency of CSF stavudine entry.